The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure

Miró, Òscar; Presa, Bernardino González de la; Herrero‐Puente, Pablo; Bonifacio, Rosa Fernández; Möckel, Martin; Mueller, Christian; Casals, Gregori; Sandalinas, Silvia; Llorens, Pere; Martín‐Sánchez, Francisco Javier; Jacob, Javier; Bedini, José Luis; Gil, Víctor

doi:10.1080/1354750x.2017.1319421

Cited by 23 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study concluded that only Gal3 was useful for predicting all-cause mortality 30 days after hospital admission for acute HF, although it had no prognostic usefulness for mortality at one year, which did show NT-proBNP. In contrast, troponin I was not useful in predicting mortality at 30 days or one year after admission [19]. In the COACH study (Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure), Gal3 was a highly useful biomarker in predicting the absence of events within 180 days after hospital discharge due to acute HF.…”

Section: St2 and Galectin-3 In Heart Failurementioning

confidence: 96%

See 1 more Smart Citation

The Role of Galectin-3 and ST2 in Cardiology: A Short Review

Merino-Merino¹,

González-Bernal

Fernandez-Zoppino

et al. 2021

Biomolecules

View full text Add to dashboard Cite

Galectin-3 is a lectin that binds beta-galactosides. It is involved in cardiac remodeling and fibrosis through the activation of macrophages and fibroblasts. ST2 is secreted by myocardial cells due to cardiac overload. These two biomarkers have been traditionally studied in the field of heart failure to guide medical therapy and detect the progression of the disease. Nevertheless, there are novel evidences that connect galectin-3 and ST2 with coronary heart disease and, specifically, with atrial fibrillation. The aim of this article is to concisely review the diagnostic and prognostic role of galectin-3 and ST2 in different cardiac diseases.

show abstract

Section: St2 and Galectin-3 In Heart Failurementioning

confidence: 96%

“…et al [6] 3353 Gal3 significantly predicted the development of IC. Miro, O. et al [19] 115 Gal3 predicted mortality one month after admission for HF.…”

Section: Authors Sample Size Main Findingsmentioning

confidence: 99%

The Role of Galectin-3 and ST2 in Cardiology: A Short Review

Merino-Merino¹,

González-Bernal

Fernandez-Zoppino

et al. 2021

Biomolecules

View full text Add to dashboard Cite

show abstract

“…Instead, galectin-3 is a good predictor of re-hospitalization for HF within 1 to 4 months, as demonstrated by a meta-analysis on 902 patients with acute HF [ 89 ]. In the GALectin-3 in Acute heart failure (GALA) study, galectin-3 measured on admission was a good predictor of 30-day mortality, but not of 1-year mortality [ 90 ]. However, sub-analyses of recent trials such as RELAXin in Acute Heart Failure (RELAX-AHF) and ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) did not find a predictive value for 6-month death [ 91 ].…”

Section: Myocardial Remodelling Inflammation and Oxidative Stressmentioning

confidence: 99%

Biomarkers for the diagnosis and management of heart failure

et al. 2021

View full text Add to dashboard Cite

Heart failure (HF) is a significant cause of morbidity and mortality worldwide. Circulating biomarkers reflecting pathophysiological pathways involved in HF development and progression may assist clinicians in early diagnosis and management of HF patients. Natriuretic peptides (NPs) are cardioprotective hormones released by cardiomyocytes in response to pressure or volume overload. The roles of B-type NP (BNP) and N-terminal pro-B-type NP (NT-proBNP) for diagnosis and risk stratification in HF have been extensively demonstrated, and these biomarkers are emerging tools for population screening and as guides to the start of treatment in subclinical HF. On the contrary, conflicting evidence exists on the role of NPs as a guide to HF therapy. Among the other biomarkers, high-sensitivity troponins and soluble suppression of tumorigenesis-2 are the most promising biomarkers for risk stratification, with independent value to NPs. Other biomarkers evaluated as predictors of adverse outcome are galectin-3, growth differentiation factor 15, mid-regional pro-adrenomedullin, and makers of renal dysfunction. Multi-marker scores and genomic, transcriptomic, proteomic, and metabolomic analyses could further refine HF management.

show abstract

“…Nevertheless, there are still discrepancies among the data in acute HF patients. Previously in relatively small studies, galectin-3 was shown to be associated with mortality (147)(148)(149)(150) and HF rehospitalization (151,152). In contrast, recently a study on a cohort of 1,161 patients with acute HF revealed that there was no correlation between galectin-3 levels and mortality among those patients (153).…”

Section: Galectin-3mentioning

confidence: 99%

Reappraisal of Inflammatory Biomarkers in Heart Failure

Chaikijurajai

Tang

2020

Curr Heart Fail Rep

View full text Add to dashboard Cite

Purpose of Review Inflammation has been shown to be an important factor in the development and progression of heart failure (HF), regardless of the etiology. There have been many studies demonstrated roles of inflammatory biomarkers in diagnosis, prognosis of chronic and acute HF patients, and also markers of cardiotoxicity from chemotherapy. These cytokines are highsensitivity C-reactive protein (hsCRP), myeloperoxidase (MPO), soluble growth stimulation expressed gene 2 (sST2), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNFα), growth differentiation factor-15 (GDF-15), endothelin-1 (ET-1), and galectin-3. In this review, we discuss the past, and present insights of those inflammatory biomarkers in order to gain more understanding in pathogenesis of HF, risk stratification of HF patients, and early detection of cardiotoxicity from cancer therapy.Recent Findings Those inflammatory cytokines have been shown to be associated with mortality of both chronic and acute HF patients, and some of them are able to track treatment responses, especially sST2 and galectin-3, which are the only two inflammatory biomarkers recommended to use in clinical setting by the recent standard HF guidelines. While some studies described ET-1 and MPO as potential predictors of cardiotoxicity from cancer drugs.Summary The prognostic implications of inflammatory biomarkers in HF patients have been demonstrated more consistently in chronic than acute HF, with some suggestions of ET-1 and MPO in patients receiving chemotherapy. However, further studies are necessary for the use of inflammatory biomarkers in routine clinical practice.

show abstract

The GALA study: relationship between galectin-3 serum levels and short- and long-term outcomes of patients with acute heart failure

Abstract: These results suggest that galectin-3 could help to monitor the risk of short-term mortality in unselected patients with AHF attended in the ED.

Cited by 23 publications

References 29 publications

The Role of Galectin-3 and ST2 in Cardiology: A Short Review

The Role of Galectin-3 and ST2 in Cardiology: A Short Review

Biomarkers for the diagnosis and management of heart failure

Reappraisal of Inflammatory Biomarkers in Heart Failure

Contact Info

Product

Resources

About